Bausch + Lomb Corporation logo

Bausch + Lomb Corporation (BLCO)

Market Closed
11 Jun, 20:00
NYSE NYSE
$
15. 29
+0.03
+0.1966%
$
5.51B Market Cap
- P/E Ratio
- Div Yield
310,011 Volume
- Eps
$ 15.26
Previous Close
Add Transaction
Day Range
15.07 15.4
Year Range
11.44 18.91
Want to track BLCO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BLCO closed today higher at $15.29, an increase of 0.1966% from yesterday's close, completing a monthly decrease of -3.9573% or -$0.63. Over the past 12 months, BLCO stock lost -10.8974%.
BLCO is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, missed the consensus estimates by -0.07%. On average, the company has fell short of earnings expectations by -0.0301%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NYSE (USD).

BLCO Chart

People also search for

FIG
Figma Inc. Class A Common Stock
$ 19.34
-2.3725%
Snap Inc.
$ 5.33
-0.9294%
GUIDEWIRE SOFTWARE INC
$ 118.52
+1.6554%
YMM
Full Truck Alliance Co. Ltd. American Depositary Receipt
$ 8.47
+1.5588%
D-Wave Quantum Inc.
$ 23.82
+2.4516%
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seekingalpha | 2 days ago
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript

Seekingalpha | 1 week ago
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win

Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win

With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.

247wallst | 4 weeks ago

Bausch + Lomb Corporation Investors

Name Quantity Cost Value Profit ($) Gain (%)
Larry Robbins
Larry Robbins Glenview Capital Management
1.91M $26.75M $29.21M $2.46M 9.2%
Point72 Asset Management LP
Point72 Asset Management LP Point72 Asset Management LP
283,138 $4.52M $4.33M -$189,044.4 -4.18%
YA
Yinka Akinsola Blue Trust Inc.
370 $4,813.7 $5,657.3 $843.6 17.52%
Christopher C. Powers
Christopher C. Powers Farther Finance Advisors, LLC
246 $4,202 $3,761.34 -$440.66 -10.49%
STEFANIE KENNEDY
STEFANIE KENNEDY Ballast Asset Management, LP
219,566 $3.68M $3.36M -$325,014.34 -8.83%

Bausch + Lomb Corporation (BLCO) FAQ

What is the stock price today?

The current price is $15.29.

On which exchange is it traded?

Bausch + Lomb Corporation is listed on NYSE.

What is its stock symbol?

The ticker symbol is BLCO.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 5.51B.

Has Bausch + Lomb Corporation ever had a stock split?

No, there has never been a stock split.

Bausch + Lomb Corporation Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Brenton L. Saunders CEO
NYSE Exchange
071705107 CUSIP
CA Country
13,500 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Bausch + Lomb Corporation is a globally recognized eye health company with operations spanning several key markets, including the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and beyond. The company is structured into three main segments: Vision Care, Pharmaceuticals, and Surgical, each catering to different aspects of eye health and treatment needs. Founded in 1853, Bausch + Lomb has established its headquarters in Vaughan, Canada, demonstrating a long-standing commitment to providing innovative eye health solutions. Operating as a subsidiary of Bausch Health Companies Inc., Bausch + Lomb utilizes both direct sales forces and independent distributors to sell its wide array of products and services across the globe.

Products and Services

  • Vision Care

    This segment offers a broad spectrum of contact lenses catering to various wearing modalities, including daily disposable and frequently replaced options. Bausch + Lomb also provides a range of contact lens care products, which includes over-the-counter eye drops, eye vitamins, and mineral supplements targeting conditions like eye allergies, conjunctivitis, dry eye, and redness relief.

  • Pharmaceuticals

    In the Pharmaceuticals segment, Bausch + Lomb offers both proprietary and generic pharmaceutical products designed for post-operative treatments, as well as for managing glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. This segment leverages innovative research to develop treatments that address some of the most pressing eye health issues faced by patients worldwide.

  • Surgical

    This segment focuses on providing medical device equipment, consumables, and technologies needed for treating a variety of eye conditions including cataracts, corneal, vitreous, and retinal issues. Bausch + Lomb offers intraocular lenses and delivery systems, phacoemulsification equipment, and other essential surgical instruments and devices needed for cataract surgery. This demonstrates the company’s commitment to supporting eye surgeons with the tools and technologies needed for effective treatment procedures.

Contact Information

Address: 520 Applewood Crescent
Phone: 905 695 7700